

AD\_\_\_\_\_

Award Number: DAMD17-03-1-0261

TITLE: Serum Genetic Markers as Surrogates of Prostate Cancer Progression

PRINCIPAL INVESTIGATOR: Dave B. Hoon, Ph.D.

CONTRACTING ORGANIZATION: John Wayne Institute for Cancer  
Santa Monica, California 90404

REPORT DATE: April 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20051101 089

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> <i>(Leave blank)</i>		<b>2. REPORT DATE</b> April 2005	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Apr 2004 - 31 Mar 2005)
<b>4. TITLE AND SUBTITLE</b> Serum Genetic Markers as Surrogates of Prostate Cancer Progression		<b>5. FUNDING NUMBERS</b> DAMD17-03-1-0261	
<b>6. AUTHOR(S)</b> Dave B. Hoon, Ph.D.			
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> John Wayne Institute for Cancer Santa Monica, California 90404		<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>			
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited		<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 Words)</b> No abstract provided.			
<b>14. SUBJECT TERMS</b> No subject terms provided.		<b>15. NUMBER OF PAGES</b> 3	
		<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited

DAMD17-03-1-0261

**PROGRESS REPORT**

Reporting period: 04/01/2004 - 03/31/2005

No progress report has been carried out on this project since AMDEX had not approved the human subjects IRB until March 2005. The only work that has been done on this project is multiple revisions and resubmissions of documents pertaining to the human subjects' protocol and consent forms. Therefore this progress report is being submitted as a formality. Recently we submitted a progress report in January 2005 to Dr. Mishra, in charge of the DOD prostate grants.

Finally, in March 2005, the prohibitions against the use of human subjects and human anatomical substances to this agreement were removed. We are now collecting serum samples from normal and prostate cancer patients. Assays are being set up rapidly to make time that has been missed. We have developed new approaches of measuring circulating DNA in serum for microsatellites and methylation of tumor-related genes in other cancers. Fortunately we can apply this to the prostate studies. In addition we have developed improved DNA extraction techniques as well as assay techniques for circulating DNA in serum. The upcoming year will be focused on developing new DNA markers as well as accruing patients and normal donors for the studies. We will also get our collaborators at U. of Washington on board by having approval of the protocol and consents from their human IRB approved.